Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Québec, H34 2B4, Canada.
The Neuro's Early Drug Discovery Unit (EDDU), Structural Genomics Consortium, McGill University, Montreal, Québec, H3A 2B4, Canada.
F1000Res. 2023 Aug 31;12:391. doi: 10.12688/f1000research.132952.1. eCollection 2023.
Superoxide dismutase [Cu-Zn] 1 (SOD1), is an antioxidant enzyme encoded by the gene , responsible for regulating oxidative stress levels by sequestering free radicals. Identified as the first gene with mutations in Amyotrophic lateral sclerosis (ALS), is a determinant for studying diseases of aging and neurodegeneration. With guidance on well-characterized anti-SOD1 antibodies, the reproducibility of SOD1 research would be enhanced. In this study, we characterized eleven SOD1 commercial antibodies for Western blot, immunoprecipitation, and immunofluorescence using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. We identified many high-performing antibodies and encourage readers to use this report as a guide to select the most appropriate antibody for their specific needs.
超氧化物歧化酶[Cu-Zn]1(SOD1)是一种由基因编码的抗氧化酶,通过隔离自由基来调节氧化应激水平。作为肌萎缩侧索硬化症(ALS)中第一个突变的基因,它是研究衰老和神经退行性疾病的决定因素。有了针对 SOD1 的经过充分验证的抗体的指导,SOD1 的研究的可重复性将会提高。在这项研究中,我们使用基于比较敲除细胞系和同基因亲本对照的读出值的标准化实验方案,对 11 种 SOD1 商业抗体进行了 Western blot、免疫沉淀和免疫荧光分析。我们鉴定了许多性能优异的抗体,并鼓励读者将本报告作为选择最适合其特定需求的抗体的指南。